reason report
posit scchn updat leerink global healthcar
confer pt
bottom line confer today spoke troy
wilson presid ceo discuss focus encourag
updat tipifarnib phase ii hrasm squamou cell carcinoma
head neck scchn tipifarnib data present today
multidisciplinari head neck cancer symposium
plan registration-en studi hrasm scchn upcom
catalyst view well posit continu
view tipifarnib activ drug manag safeti profil
increas pt previous reflect increas
confid manag abil execut strategi develop
tipifarnib hra mutant hrasm squamou cell carcinoma head
neck scchn recal licens world-wide right tipifarnib
indic virolog janssen op
previous evalu tipifarnib broadli across variou hematolog
solid tumor limit success believ precis medicin
approach develop tipifarnib biomarker-defin patient offer
opportun improv past effort
encourag updat hrasm scchn phase ii studi
confirm partial respons pr one stabl diseas sd
achiev six evalu hrasm scchn patient includ
durabl respons month two patient three
addit patient enrol sinc last updat octob
none three patient evalu feb
data cutoff date three patient come studi one
withdrew consent one die unrel studi drug recal
last provid encourag updat phase ii tipifarnib studi
hrasm scchn aacr-nci-eortc intern confer
molecular target tripl meet
oral present previous announc hrasm
scchn studi formal posit per studi protocol four
confirm partial respons pr two stabl diseas sd
first six evalu scchn patient enrol studi two
respons demonstr durabl beyond one year view earli
data particularli strike given signific unmet medic need
line recurrent/metastat scchn exist line therapi
pembrolizumab nivolumab cetuximab demonstr respons
rate limit durat clinic benefit median
multipl dr tgr
compani inform leerink partner llc research
pleas refer page import disclosur price chart analyst certif
initi registration-en studi hrasm scchn
previou convers manag disclos
expect respons rate driven registration-en studi
patient upper end studi size potenti run
smaller studi note keytruda receiv acceler
approv scchn efficaci patient
studi orr expect regul would requir
smaller studi given impress efficaci achiev
data multidisciplinari head neck cancer symposium
preclin data hra mutant squamou non-smal cell lung cancer
nsclc tumor model phase ii data myelodysplast
syndrom md peripher cell lymphoma chronic
myelomonocyt leukemia cmml like initi
registration-en studi hrasm scchn
preclin biomark data phase dose escal
data
increas pt previous made
sever chang model includ increas probabl
success po tipifarnib hrasm scchn
previous base increas confid manag
abil execut develop strategi scchn
acceler enrol observ on-going phase ii studi
expect reason size scchn pivot studi link
also separ break tipifarnib opportun hrasm
squamou nsclc base plan evalu opportun part
cooper group studi genom data highlight
investor day suggest share pathway squamou cell carcinoma
rate share outperform view lead pipelin program
tipifarnib farnesyltransferas inhibitor activ drug manag safeti profil
licens world-wide right tipifarnib indic virolog janssen
previous evalu tipifarnib broadli across variou hematolog solid tumor
limit success believ precis medicin approach develop tipifarnib
biomarker-defin patient offer opportun improv past effort base review
literatur medacorp kol check believ investor focu continu
lead clinic asset tipifarnib inhibitor menin-ml mix lineag
price target base blend dcf analysi revenu
multipl analysi assign valu probability-weight us sale tipifarnib hra mutant
squamou cell carcinoma head neck scchn probabl success hra
mutant squamou non-smal cell lung cancer nsclc probabl success hra
mutant solid tumor probabl success peripher cell lymphoma
probabl success myelodysplast syndrom md probabl success
cmml probabl success assum royalti ex-u tipifarnib sale
futur partnership earlier stage program menin-ml inhibitor repres
upsid valuat use discount rate termin growth rate
pipelin program face clinic regulatori develop risk well commerci
intellectu properti risk also face execut risk financi risk may
addit financ need turn cash flow posit
leerink partner estim compani file
chang
oper
invest
financ
leerink partner estim compani file
pipelin upcom event
janssen
multidisciplinari head
potenti acut
hrasm solid tumor
